Furthermore, the clinical validation cohort was limited to 104 GC patients, and data on immunotherapy efficacy were not available, preventing us from assessing the potential value of GNGT1 predicting immunotherapy efficacy. This evidence concerns the gene GNGT1 and gastric cancer.